MedPath

RHEACELL GmbH & Co. KG

RHEACELL GmbH & Co. KG logo
🇩🇪Germany
Ownership
Private
Established
2003-01-01
Employees
101
Market Cap
-
Website
http://www.rheacell.com

Clinical Trials

30

Active:18
Completed:3

Trial Phases

3 Phases

Phase 1:25
Phase 2:2
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
25 (83.3%)
Phase 3
3 (10.0%)
Phase 2
2 (6.7%)

CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS

Phase 3
Active, not recruiting
Conditions
chronic venous ulcers (CVU)
First Posted Date
2024-07-05
Last Posted Date
2025-10-01
Lead Sponsor
Rheacell GmbH & Co. KG
Target Recruit Count
230
Registration Number
2024-512720-11-00
Locations
🇬🇧

RHEACELL Clinical Trial Site, Multiple Locations, United Kingdom

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Phase 3
Recruiting
Conditions
Epidermolysis Bullosa
Interventions
Drug: Placebo
First Posted Date
2023-05-01
Last Posted Date
2023-10-30
Lead Sponsor
RHEACELL GmbH & Co. KG
Target Recruit Count
74
Registration Number
NCT05838092
Locations
🇺🇸

Masonic Cancer Center and Medical Center Minneapolis, Minneapolis, Minnesota, United States

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

Phase 3
Recruiting
Conditions
Epidermolysis Bullosa
Interventions
Drug: Placebo
First Posted Date
2022-07-19
Last Posted Date
2023-02-24
Lead Sponsor
RHEACELL GmbH & Co. KG
Target Recruit Count
74
Registration Number
NCT05464381
Locations
🇦🇹

EB-Haus Austria; Salzburger Landeskliniken (SALK), Salzburg, Austria

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Phase 2
Recruiting
Conditions
Skin Ulcer Venous Stasis Chronic
Interventions
First Posted Date
2021-07-21
Last Posted Date
2024-08-26
Lead Sponsor
RHEACELL GmbH & Co. KG
Target Recruit Count
200
Registration Number
NCT04971161
Locations
🇩🇪

MVZ Gefäßzentrum Aachen am Marienhospital Aachen GmbH, Aachen, Germany

🇩🇪

Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany

🇩🇪

Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany

and more 35 locations

Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

Phase 1
Terminated
Conditions
Acute-On-Chronic Liver Failure
First Posted Date
2019-03-01
Last Posted Date
2021-11-17
Lead Sponsor
RHEACELL GmbH & Co. KG
Target Recruit Count
5
Registration Number
NCT03860155
Locations
🇩🇪

Universitätsklinikum Carl-Gustav-Carus an der TU Dresden, Medizinische Klinik I, Dresden, Germany

🇩🇪

Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie, Medizinisches Forschungszentrum, Essen, Germany

🇩🇪

Universitätsklinikum Frankfurt, Medizinische Klinik 1, Sektion Translationale Hepatologie, Frankfurt, Germany

and more 2 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.